Book Cover
Home  |   Healthcare   |  Osteoarthritis Market

Osteoarthritis Market Size, Share, Growth, and Industry Analysis, By Type (Medication, Surgery, Therapy), By Application (Hospitals, Medical Institutes), Regional Insights and Forecast to 2035

Trust Icon
1000+
GLOBAL LEADERS TRUST US

Osteoarthritis Market Overview

The global Osteoarthritis Market is projected to experience sustained growth from USD 9859.6 Million in 2026 to USD 21857.14 Million by 2035, exhibiting a CAGR of 9.25% during the forecast period 2026-2035.

Metric Value
Largest Region North America (34%)
Largest Application Hospitals (68%)
Largest Product Type Medication (46%)
Fastest-Moving Product Trend Regenerative Therapies, Precision Medicine, AI-Assisted Joint Replacement, Weight Management and Personalized Rehabilitation
Leading Companies Pfizer Inc (4%), Johnson & Johnson (4%)

The global Osteoarthritis Market is expanding as aging populations, increasing obesity prevalence and greater demand for effective joint pain management reshape healthcare requirements. Approximately 73% of people affected by osteoarthritis are older than 55, demonstrating the substantial influence of demographic aging on treatment demand. Osteoarthritis is a chronic joint condition involving cartilage deterioration, changes in surrounding bone, inflammation and reduced mobility. The knees, hips, hands and spine are commonly affected, creating requirements for medication, rehabilitation and surgical intervention. Healthcare professionals increasingly emphasize individualized management involving exercise, weight control, appropriate pain relief and functional assessment. Pharmaceutical companies and orthopedic technology providers are investigating improved therapeutic approaches, including targeted biological pathways, joint preservation and advanced surgical techniques. Rising awareness of long-term disability encourages earlier clinical evaluation and coordinated treatment.

The USA Osteoarthritis Market benefits from established orthopedic healthcare infrastructure, specialized rehabilitation services and extensive clinical research activity. More than 33 million adults in the United States are affected by osteoarthritis, reinforcing the importance of accessible diagnosis and effective long-term management. American hospitals provide medication management, physical therapy, orthopedic assessments and joint replacement procedures for patients experiencing persistent pain and movement limitations. Healthcare organizations increasingly examine treatment effectiveness, patient-reported outcomes and recovery requirements before selecting interventions. Johnson & Johnson maintains an important orthopedic technology presence, while pharmaceutical developers investigate therapies addressing pain and underlying disease mechanisms. Growing interest in robotic-assisted surgery, personalized rehabilitation and nonsurgical intervention continues to influence healthcare purchasing decisions. Insurance coverage, specialist availability and treatment affordability remain important considerations for patients and providers.

Global Osteoarthritis Market Size, 2035 (USD Million)

Get Comprehensive Insights into the Market’s Size and Growth Trends

downloadDownload FREE Sample

Key Findings

  • Market Driver: Population aging remains a fundamental growth driver, with 73% of people living with osteoarthritis older than 55, reinforcing demand for pain management, rehabilitation and orthopedic services.
  • Major Market Restraint: Affordability and unequal access to advanced treatment restrict patient care, with 42% of patients identified in the referenced market assessment as facing cost-related limitations on specialized interventions.
  • Emerging Trends: Regenerative medicine and biological treatment research are receiving greater attention, with 51% of emerging treatment activity attributed to biologic or regenerative approaches in the referenced development assessment.
  • Regional Leadership: North America leads the modeled geographic allocation with 34% share, supported by established orthopedic healthcare facilities, specialist treatment availability, advanced surgical technology and clinical research activity.
  • Competitive Landscape: Johnson & Johnson holds approximately 4% of the global Osteoarthritis Market, supported by its established orthopedic technology portfolio, advanced joint reconstruction capabilities, robotic-assisted surgical innovations, and continued investment in precision surgical technologies.
  • Market Segmentation: Medication leads the reported treatment segmentation with 46% share, while Hospitals account for a modeled 68% of application demand, reflecting established prescribing practices and specialized orthopedic services.
  • Recent Development: Eli Lilly and Company reported a 73% reduction in knee osteoarthritis pain with investigational retatrutide in a clinical study, highlighting the potential of metabolic treatment approaches for patients with obesity.

The Osteoarthritis Market is witnessing increasing research activity involving disease-modifying therapies, regenerative medicine and treatments directed toward specific biological mechanisms. Approximately 51% of emerging therapeutic development activity is associated with biologic or regenerative approaches in the referenced market assessment, reflecting interest in strategies beyond conventional pain management. Researchers are investigating cartilage repair, inflammatory signaling, subchondral bone changes and molecular pathways contributing to joint deterioration. 

Another important trend involves personalized rehabilitation, metabolic risk management and technology-assisted orthopedic procedures. Approximately 57% shorter landmark identification workflow time was reported for an AI-assisted hip navigation approach compared with manual identification, demonstrating potential operational advantages in selected surgical settings. Healthcare providers increasingly combine imaging, clinical assessments and functional measurements to guide treatment decisions. 

Osteoarthritis Market Dynamics

Driver

"Aging populations and increasing joint disease prevalence strengthen treatment demand."

Population aging remains a major factor supporting demand across the Osteoarthritis Market. Approximately 73% of people living with osteoarthritis are older than 55, reflecting the relationship between advancing age and degenerative joint conditions. Age-related changes in cartilage, muscle strength and joint structures can contribute to pain, stiffness and mobility difficulties. Healthcare professionals increasingly encounter patients requiring sustained treatment rather than temporary symptom management. 

Increasing obesity prevalence and musculoskeletal health concerns further reinforce demand for osteoarthritis management. Approximately 60% of people affected by osteoarthritis are female, demonstrating important differences in disease burden across demographic groups. Excess body weight can increase mechanical loading on weight-bearing joints while contributing to metabolic processes associated with inflammation. Previous joint injuries, occupational activities and genetic factors also influence individual risk.

Restraint

"Treatment expenses and limited specialist accessibility constrain patient care."

High treatment expenses and unequal healthcare access remain significant barriers to comprehensive osteoarthritis management. Approximately 42% of patients were identified in the referenced market assessment as experiencing cost-related limitations when seeking advanced treatment options. Surgical procedures, specialist consultations, prolonged rehabilitation and some injectable interventions can create financial challenges, particularly where insurance coverage is limited. Patients may delay clinical evaluation or rely on intermittent pain relief despite persistent mobility problems. 

Limited access to rehabilitation and specialized orthopedic services creates another important market restraint. Approximately 65% of the global population requiring osteoarthritis rehabilitation may face substantial service gaps under a broad comparison of rehabilitation needs and available resources, although the precise treatment-access share is not independently established. Rural communities and developing healthcare systems may experience shortages of physical therapists, orthopedic surgeons and diagnostic facilities. 

Opportunity

"Emerging therapies and personalized rehabilitation expand treatment possibilities."

Development of more targeted osteoarthritis therapies represents a significant opportunity for pharmaceutical companies and biotechnology researchers. Approximately 73% knee pain reduction was reported in a clinical assessment of investigational retatrutide, highlighting interest in metabolic treatment approaches for patients experiencing obesity-associated osteoarthritis. Research increasingly investigates relationships between body weight, inflammation, pain signaling and joint function. 

Expansion of structured rehabilitation and preventive musculoskeletal care creates additional opportunities for healthcare organizations. Approximately 344 million people living with osteoarthritis experience moderate or severe symptoms that could benefit from rehabilitation, demonstrating substantial unmet functional care requirements. Exercise-based treatment, patient education, weight management and movement training remain central elements of recommended management. Healthcare providers are increasingly exploring multidisciplinary programs that combine physical therapists, physicians and nutrition specialists. 

Challenge

"Limited disease-modifying treatments complicate long-term clinical management."

Developing therapies that reliably slow or reverse structural osteoarthritis progression remains a major industry challenge. Approximately 56% of the worldwide osteoarthritis burden involves knee disease in a recent epidemiological assessment, making effective knee-focused treatment development particularly important. Existing care primarily addresses symptoms, physical function and joint protection rather than consistently restoring damaged cartilage. Investigational treatments must demonstrate meaningful improvements while meeting demanding safety and regulatory requirements. 

Maintaining long-term patient adherence presents another important challenge for healthcare professionals. Approximately 73% of affected individuals are older than 55, and many must manage osteoarthritis alongside other chronic medical conditions. Regular exercise, appropriate medication use, weight management and rehabilitation attendance can become difficult when patients experience persistent pain or limited mobility. Treatment plans require adjustment according to functional capacity, personal preferences and medical risks. 

Osteoarthritis Market Segmentation 

Global Osteoarthritis Market Size, 2035

Get Comprehensive Insights on the Market Segmentation in this Report

download Download FREE Sample

By Types

Medication: Medication represents the leading treatment category within the Osteoarthritis Market, encompassing pharmaceutical approaches used to relieve pain and improve daily function. The category holds approximately 46% of the reported treatment distribution, reflecting extensive use of oral and topical pain-relieving medicines. Nonsteroidal anti-inflammatory drugs remain important treatment options when selected according to individual clinical risks. Healthcare professionals may also consider intra-articular corticosteroid injections for appropriate patients requiring short-term symptom relief.

Surgery: Surgery represents an essential treatment category for patients experiencing severe joint deterioration and persistent functional limitations despite appropriate nonsurgical management. The category accounts for approximately 38% of the reported treatment distribution, although this classification should not be interpreted as the proportion of all patients receiving surgery. Joint replacement procedures are commonly considered for advanced hip and knee osteoarthritis when pain and disability substantially affect quality of life. 

Therapy: Therapy includes rehabilitation-oriented approaches intended to improve joint mobility, muscular strength, physical function and confidence in everyday activities. The category represents approximately 16% of the reported treatment distribution, with demand supported by clinical recommendations emphasizing exercise and individualized self-management. Physical therapy programs commonly incorporate strengthening exercises, movement training, education and appropriate activity modification.

By Applications

Hospitals: Hospitals represent the leading application category for osteoarthritis management because they provide coordinated access to specialist assessment, medication and advanced interventions. This segment accounts for approximately 68% of the modeled application allocation, reflecting the assumed concentration of surgical and complex treatment activity within hospital settings. Orthopedic departments evaluate patients with persistent pain, joint instability and mobility limitations. 

Medical Institutes: Medical Institutes contribute through clinical research, specialist consultation, professional education and structured rehabilitation programs supporting osteoarthritis management. The segment represents approximately 32% of the modeled application allocation, reflecting the role assigned to academic medical centers and specialized research institutions within this two-category framework. These institutions investigate disease mechanisms, evaluate treatment effectiveness and develop clinical assessment methods. 

Osteoarthritis Market Regional Outlook

Global Osteoarthritis Market Share, by Type 2035

Get Comprehensive Insights into the Market’s Size and Growth Trends

download Download FREE Sample

North America

North America maintains a leading position in the Osteoarthritis Market through established orthopedic infrastructure, specialized clinical services and substantial demand for chronic joint disease management. The region represents approximately 34% of the modeled global market allocation, reflecting its assumed concentration of treatment activity within the geographic framework. The United States remains an important center for orthopedic procedures, pharmaceutical development and rehabilitation services. Canada contributes through organized healthcare systems and increasing attention to musculoskeletal health. Hospitals increasingly evaluate advanced implants, surgical navigation and patient-centered recovery approaches. Regional demand is supported by population aging and the need for effective management of persistent joint pain.

Europe

Europe represents a substantial market for osteoarthritis treatment through developed healthcare infrastructure and growing demand for mobility-preserving interventions. The region accounts for approximately 26% of the modeled global allocation, supported by orthopedic services across Germany, the United Kingdom, France, Italy and other European countries. Healthcare systems commonly emphasize conservative management, physiotherapy and appropriate pharmacological treatment before recommending major surgery. Aging populations increase requirements for joint assessment and rehabilitation. European medical institutions also contribute to pharmaceutical studies and orthopedic research. Cost-effectiveness and evidence-based treatment selection remain important considerations across public and private healthcare systems.

Asia-Pacific

Asia-Pacific represents an important osteoarthritis treatment market through large patient populations, healthcare modernization and increasing demand for orthopedic services. The region accounts for approximately 27% of the modeled geographic allocation, reflecting substantial potential treatment activity across China, India, Japan, South Korea and Australia. Population aging, changing lifestyles and increasing awareness of joint disorders support healthcare demand. Hospitals are expanding orthopedic evaluation and rehabilitation capabilities in major urban centers. Access to specialized interventions varies considerably between countries and healthcare systems. Pharmaceutical treatments and structured physical therapy remain important approaches for managing symptoms across diverse patient populations.

Middle East and Africa

Middle East and Africa presents developing opportunities for osteoarthritis management as healthcare investment and awareness of chronic musculoskeletal conditions increase. The region receives approximately 9% of the modeled global allocation, reflecting a smaller assigned position than more established treatment markets. Saudi Arabia, the United Arab Emirates, South Africa and other regional economies are expanding specialized medical facilities and rehabilitation capabilities. Increasing obesity prevalence and changing population demographics contribute to demand for joint pain management. Treatment availability differs substantially across urban and rural communities. Hospitals increasingly prioritize orthopedic services while addressing limitations involving specialist access and affordability.

Rest of the World

Rest of the World includes additional osteoarthritis treatment activity across Latin America and smaller healthcare markets outside the principal regional groupings. The category represents approximately 4% of the modeled global allocation, reflecting a limited assigned share within this analytical framework rather than an independently audited regional market measurement. Brazil, Mexico and other Latin American countries contribute demand through aging populations and established orthopedic care networks. Healthcare access differs between major urban hospitals and underserved communities. Medication and physical therapy remain important treatment options where specialized surgical services are less accessible. Increasing awareness of musculoskeletal disability encourages attention to affordable long-term care.

List of Top Osteoarthritis Market Companies

  • Abbott
  • Novartis AG
  • Pfizer Inc
  • Eli Lilly and Company
  • ABIOGEN PHARMA S.p.A
  • Merck Sharp & Dohme Corp
  • TissueGene Inc
  • Ampio Pharmaceuticals Inc
  • Regeneron
  • Johnson & Johnson

Top Two Companies with Highest Market Share

  • Pfizer Inc: Pfizer Inc holds approximately 4% of the global Osteoarthritis Market in the referenced competitive assessment, supported by its established pharmaceutical portfolio, extensive distribution network, pain management expertise and continued involvement in therapeutic research addressing joint disorders.
  • Johnson & Johnson: Johnson & Johnson accounts for approximately 4% of the global Osteoarthritis Market in the referenced competitive assessment, supported by its orthopedic technology portfolio, joint reconstruction capabilities, established healthcare relationships and development of advanced surgical solutions.

Investment Analysis and Opportunities

Investment opportunities within the Osteoarthritis Market increasingly emphasize targeted pharmaceutical development, advanced surgical technology and accessible rehabilitation services. Approximately 344 million individuals worldwide experience osteoarthritis symptoms that could benefit from rehabilitation, demonstrating substantial demand for effective functional treatment strategies. Healthcare investors are evaluating technologies that improve orthopedic assessment, surgical planning and recovery coordination. 

Emerging pharmaceutical research offers additional opportunities for companies addressing obesity-associated osteoarthritis and persistent joint pain. Approximately 73% improvement in knee pain was reported in an investigational retatrutide study, indicating potential benefits of therapies targeting metabolic contributors to disease. Research programs increasingly examine how weight reduction, inflammatory processes and joint function interact. 

New Product Development

New product development in the Osteoarthritis Market increasingly focuses on biological treatments, metabolic therapies and more precise orthopedic interventions. Eli Lilly and Company reported up to 73% reduction in knee osteoarthritis pain with investigational retatrutide, demonstrating a potentially important relationship between weight management and symptom improvement in selected patients. The treatment remains investigational, and the findings do not establish approval for osteoarthritis. 

Orthopedic technology development increasingly incorporates artificial intelligence, surgical navigation and improved joint reconstruction workflows. Johnson & Johnson reported a 57% reduction in selected landmark identification workflow time using VELYS Hip Navigation with AI Assistance compared with manual identification. The company is also investigating miniature radiofrequency tracking technology for navigation and robotic applications. These developments aim to improve procedural consistency and simplify technical workflows, although their wider clinical benefits require appropriate evaluation.

Five Recent Developments

Date Company Recent Development
April 2026 Novartis AG Novartis updated its ONWARDS knee osteoarthritis study record, documenting termination of the LNA043 investigation because efficacy endpoints were not met, with no identified safety concern responsible for the decision.
May 2026 Johnson & Johnson Johnson & Johnson's DePuy Synthes announced an agreement to acquire selected rights to Gemtrack miniature radiofrequency tracking technology for future navigation and robotic applications across joint reconstruction procedures.
June 2026 Eli Lilly and Company Eli Lilly announced clinical findings from its retatrutide development program demonstrating meaningful reductions in knee osteoarthritis pain among participants with obesity, supporting further investigation of metabolic treatment approaches.
July 2026 TissueGene Inc TissueGene announced topline results from its ACTiVION-II Phase III study of TG-C for knee osteoarthritis, advancing evaluation of an investigational cell-based gene therapy intended to improve patient symptoms.
October 2026 Pfizer Inc Pfizer's published clinical development outlook included investigation of berobenatide for knee osteoarthritis, reflecting increasing interest in metabolic medicines for obesity-associated joint symptoms; the available disclosure does not establish an October product launch.

Future Outlook

The Osteoarthritis Market report evaluates the treatment landscape across medication, surgery and therapy, examining the clinical and operational factors influencing demand. It addresses disease prevalence, demographic pressures, healthcare accessibility, treatment effectiveness and technological advancement. The assessment explores the roles of hospitals and medical institutes in delivering orthopedic care, supporting rehabilitation and investigating new therapies. 

The report also examines geographic differences in healthcare infrastructure, specialist availability, research capabilities and rehabilitation access. It considers opportunities involving pharmaceutical innovation, regenerative medicine, metabolic treatment approaches and technology-assisted orthopedic procedures. The analysis distinguishes established clinical interventions from experimental therapies that require further safety and effectiveness evaluation. Regional assessments address the influence of aging populations, healthcare investment and availability of appropriate treatment services. 

Osteoarthritis Market Report Coverage

REPORT COVERAGE DETAILS

Market Size Value In

USD 9859.6 Million in 2026

Market Size Value By

USD 21857.14 Million by 2035

Growth Rate

CAGR of 9.25% from 2026-2035

Forecast Period

2026 - 2035

Base Year

2025

Historical Data Available

Yes

Regional Scope

Global

Segments Covered

By Type :

  • Medication
  • Surgery
  • Therapy

By Application :

  • Hospitals
  • Medical Institutes

To Understand the Detailed Market Report Scope & Segmentation

download Download FREE Sample

Frequently Asked Questions

The global Osteoarthritis Market is expected to reach USD 21857.14 Million by 2035.

The Osteoarthritis Market is expected to exhibit a CAGR of 9.25% by 2035.

Abbott, Novartis AG, Pfizer Inc, Eli Lilly and Company, ABIOGEN PHARMA S.p.A, Merck Sharp & Dohme Corp, TissueGene Inc, Ampio Pharmaceuticals Inc, Regeneron, Johnson & Johnson

In 2026, the Osteoarthritis Market value will reach at USD 9859.6 Million.

faq right

Our Clients

Captcha refresh

Trusted & Certified